Abstract
Chronic lymphocytic leukemia (CLL) has an extremely heterogeneous prognosis. Nowadays, the median survival of patients with this form of leukemia is 8–10 years, compared with 5–6 years in series reported in the 1970s. This is largely due to the higher number of patients who are now being diagnosed in early phase (up to 80%) and, hence, with better prognosis [1, 2]. Individual survival, however, is highly variable.